Your browser doesn't support javascript.
loading
Características basales, manejo de terapias antitrombóticas y pronóstico de pacientes chilenos con FA no valvular. Lecciones del Registro GARFIELD AF en Chile / Features, management and prognosis of Chilean patients with non valvular atrial fibrillation: GARFIELD AF registry
Corbalán, Ramón; Conejeros, Carlos; Rey, Carlos; Stockins, Benjamín; Eggers, Germán; Astudillo, Carlos; Lanas, Fernando; Potthoff, Sergio; Houzvic, César; Montecinos, Humberto; Charme, Gustavo; Bugueño, Claudio; Aguilar, Juan; Arriagada, Germán; Marín, Patricio; Larico, Martín.
  • Corbalán, Ramón; Pontificia Universidad Católica de Chile. Escuela de Medicina. División Enfermedades Cardiovasculares. Santiago. CL
  • Conejeros, Carlos; Pontificia Universidad Católica de Chile. Escuela de Medicina. División Enfermedades Cardiovasculares. Santiago. CL
  • Rey, Carlos; Pontificia Universidad Católica de Chile. Escuela de Medicina. División Enfermedades Cardiovasculares. Santiago. CL
  • Stockins, Benjamín; Pontificia Universidad Católica de Chile. Escuela de Medicina. División Enfermedades Cardiovasculares. Santiago. CL
  • Eggers, Germán; Pontificia Universidad Católica de Chile. Escuela de Medicina. División Enfermedades Cardiovasculares. Santiago. CL
  • Astudillo, Carlos; Pontificia Universidad Católica de Chile. Escuela de Medicina. División Enfermedades Cardiovasculares. Santiago. CL
  • Lanas, Fernando; Pontificia Universidad Católica de Chile. Escuela de Medicina. División Enfermedades Cardiovasculares. Santiago. CL
  • Potthoff, Sergio; Pontificia Universidad Católica de Chile. Escuela de Medicina. División Enfermedades Cardiovasculares. Santiago. CL
  • Houzvic, César; Pontificia Universidad Católica de Chile. Escuela de Medicina. División Enfermedades Cardiovasculares. Santiago. CL
  • Montecinos, Humberto; Pontificia Universidad Católica de Chile. Escuela de Medicina. División Enfermedades Cardiovasculares. Santiago. CL
  • Charme, Gustavo; Pontificia Universidad Católica de Chile. Escuela de Medicina. División Enfermedades Cardiovasculares. Santiago. CL
  • Bugueño, Claudio; Pontificia Universidad Católica de Chile. Escuela de Medicina. División Enfermedades Cardiovasculares. Santiago. CL
  • Aguilar, Juan; Pontificia Universidad Católica de Chile. Escuela de Medicina. División Enfermedades Cardiovasculares. Santiago. CL
  • Arriagada, Germán; Pontificia Universidad Católica de Chile. Escuela de Medicina. División Enfermedades Cardiovasculares. Santiago. CL
  • Marín, Patricio; Pontificia Universidad Católica de Chile. Escuela de Medicina. División Enfermedades Cardiovasculares. Santiago. CL
  • Larico, Martín; Pontificia Universidad Católica de Chile. Escuela de Medicina. División Enfermedades Cardiovasculares. Santiago. CL
Rev. méd. Chile ; 145(8): 963-971, ago. 2017. tab, graf
Article in Spanish | LILACS | ID: biblio-902573
ABSTRACT

Background:

Atrial fibrillation (AF) is the most common cardiac arrhythmia and is associated with high rates of death, ischemic stroke and systemic embolism (SE). There is scarce information about clinical characteristics and use of anti-thrombotic therapies in Chilean patients with non-valvular AF.

Aim:

To describe the characteristics and 1-year outcomes of patients with recently diagnosed AF recruited in Chile into the prospective global GARFIELD-AF registry. Material and

Methods:

Between 2011-2016, we prospectively registered information of 971 patients recruited at 15 centers, 85% of them from the public system and 15% from the private sector. Demographics, clinical characteristics and use of antithrombotic therapies were recorded for all patients. Adverse clinical outcomes were analyzed in 711 patients with 1-year follow-up.

Results:

The mean age was 71.5 years (66-79), 50% were men. Mean CHAD2S2 Vasc and HAS BLED scores for stroke risk were 3.3 (2.0-4.0) and 1.5 (1.0-2.0) respectively. Oral anticoagulants were prescribed in 82% of patients. Seventy percent received Vitamin K antagonists, 10% novel direct anticoagulants or antiplatelet therapy and only 8% did not receive any antithrombotic therapy. Mean time in optimal therapeutic range (an international normalized ratio of 2 to 3), was achieved in only 40.7% (23.0-54.8) of patients receiving Vitamin K antagonists. One year rates of death, stroke/systemic embolism and bleeding were 4.75 (3.36-6.71), 2.40 (1.47-3.92) and 1.64% (0.91-2.97) per 100 person-years. Ischemic stroke occurred in 1.8% and hemorrhagic stroke in 0.8% of patients at 1-year of follow up.

Conclusions:

Although the use of vitamin K antagonists at baseline was high, the mean time in optimal therapeutic range was low. Mortality and stroke rates are higher than those reported in other contemporary registries.
Subject(s)


Full text: Available Index: LILACS (Americas) Main subject: Atrial Fibrillation / Fibrinolytic Agents Type of study: Etiology study / Observational study / Prognostic study / Risk factors Limits: Aged / Female / Humans / Male Country/Region as subject: South America / Chile Language: Spanish Journal: Rev. méd. Chile Journal subject: Medicine Year: 2017 Type: Article Affiliation country: Chile Institution/Affiliation country: Pontificia Universidad Católica de Chile/CL

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Index: LILACS (Americas) Main subject: Atrial Fibrillation / Fibrinolytic Agents Type of study: Etiology study / Observational study / Prognostic study / Risk factors Limits: Aged / Female / Humans / Male Country/Region as subject: South America / Chile Language: Spanish Journal: Rev. méd. Chile Journal subject: Medicine Year: 2017 Type: Article Affiliation country: Chile Institution/Affiliation country: Pontificia Universidad Católica de Chile/CL